Pinsent Masons advises on the acquisition by EFI of the Rhapso group

16 Apr 2014 | 10:07 am |

International law firm Pinsent Masons has advised Electronics For Imaging (EFI), a Californian NASDAQ-listed global player in digital imaging solutions, on the acquisition of the Rhapso group, a French printing and packaging software developer.

The transaction will enable EFI to strengthen its position in Europe through Rhapso's Graphisoft and PC-Topp product lines.
The Pinsent Masons multidisciplinary team acting on the deal was led by Paris-based partner Christophe Clerc, with Philippe Malikian and Romain Castelli on Corporate matters, and Jean-François Rage and Jean-Sébastien Lipski on Employment law matters.

Latest press releases

Show me all press releases

Pinsent Masons advises Bodymed AG on the sale to Nestlé Health Science

The multinational law firm Pinsent Masons advises the holding company of the founder Dr Hardy Walle on the sale of all shares of Bodymed AG to Nestlé Health Science.

Pinsent Masons secures 11th place in Financial Times Diversity Leaders 2021 Report

Multinational law firm Pinsent Masons has been named as a top 20 Diversity Leader by the Financial Times, ranked 11th in its Diversity Leaders 2021 report.

Pinsent Masons advises shareholders of Goodtill on its sale to SumUp

Multinational law firm Pinsent Masons has advised the shareholders of Goodtill on its sale to SumUp

People who viewed this press release also viewed

Show me all press releases

Pinsent Masons advises Bodymed AG on the sale to Nestlé Health Science

The multinational law firm Pinsent Masons advises the holding company of the founder Dr Hardy Walle on the sale of all shares of Bodymed AG to Nestlé Health Science.

Pinsent Masons advises shareholders of Goodtill on its sale to SumUp

Multinational law firm Pinsent Masons has advised the shareholders of Goodtill on its sale to SumUp

Pinsent Masons advises 4D Pharma PLC on innovative move to NASDAQ

Multinational law firm Pinsent Masons has advised AIM listed biotech company 4D Pharma plc (4D) on its acquisition of Longevity Acquisition Corporation, a special-purpose acquisition company (SPAC) listed on NASDAQ. Upon completion of the transaction 4D will apply for its American Depositary Shares to be admitted to trading on NASDAQ.

For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on

+44 (0)20 7418 8199 or 

Location contacts